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Abstract
There are three theories of cancer development analyzed in this review. The first theory is the immunological theory, which states
that cancer is a result of the immune system failing to detect a cancerous cell in which results in uncontrolled cell growth.The second
theory is the somatic mutation theory, which states that genetic mutations are a direct cause cancer. The third theory is the stem
cell theory which states that cancer results from an uncontrolled stem cell. The difference in each theory helps guide a clinician’s
judgment in how to treat cancer. If a clinician believes in the immunological theory, he/she will view the best route of treatment as
being by targeting the patient’s immune system. One who believes somatic mutation theory would say that the patient’s genetic
makeup of the patient is the ideal target for treatment. One who believes in the stem cell theory would say that the only method of
treatment is to remove the cancer entirely as any residual cancer will return. Based on all the evidence it appears that there is not
one individual factor that causes cancer development, rather it is a combination of several factors that result in cancer.
Introduction
In 2013 cancer was reported to affect over 1.6 million
people (Siegel, et al., 2013). Despite cancer being such a
highly discussed and researched disease there are many
things that remain unknown. One of the major debates is
how cancer develops; there are three major schools of
thought: the immunological theory, the somatic mutation
theory, and the stem cell theory.
The immunological theory postulates that cancer develops as a result of the immune system failing to detect
the cancerous cell. As a result of an undetected cell the
cancer grows at an uncontrolled and dangerous rate,
thereby damaging the host. If this is the sole etiology of
cancer, the immune system could be harnessed to treat
a person who had developed cancer. For example, a new
cancer vaccine has been developed for prostate cancer
patients. This vaccine was developed for two reasons.
Firstly, prostate cancer cells have several tumor-associated antigens. Secondly, because the prostate is a nonessential organ, annihilation of any normal prostate tissue that
comes about because of the immune response has no
clinical consequence (Singh & Gulley, 2014). While not all
cancers have these qualifications that make them susceptible to a vaccine, other forms of immunotherapies are in
development to try and take advantage of the specifics of
each cancer to attack it immunologically.
The somatic mutation theory postulates cancer develops due to a genetic mutation leading to uncontrolled
growth. A study showed that there are specific gene mutations involved in breast and ovarian cancer. These are
mutations of either the BRCA1 or BRCA2 gene (Miki,
et al., 1994). More specifically, it has been shown that
women with BRCA1 mutation by age 80 have a 72 percent chance of developing breast cancer. While women
who have the BRCA 2 mutation have a 69 percent chance
of developing breast cancer (Kuchenbaecker, et al., 2017).
Treatments based on this theory focuses more on the
genetics of a person and using that field as a method to
control or treat the cancer.
The stem cell theory of cancer assumes that cancer develops because there is an uncontrolled stem cell in the

body. All humans develop from stem cells that multiply
repeatedly. However, during human development stem
cells become specialized and eventually stop multiplying.
This theory of cancer development says that cancer results from a stem cell that has not “turned off”, resulting
in uncontrolled growth to the point of being detrimental
to the host. This theory has many implications. Some clinicians evaluate a cancer treatment based on how much
it causes the tumor to shrink, but without removing the
source the tumor will come back very quickly because
the stem cells are still there. Physicians and Oncologists
who subscribe to the stem cell theory may treat cancers
differently than those who believe in the immunological
theory or the somatic mutation theory.
The significance of each theory is that the information
regarding how the disease develops can help determine
the best course of treatment. Evidence seems to point to
all three of these theories, hence there is no conclusive
explanation. This review will examine all the evidence in
order to determine which hypothesis best explains the
development of cancer.
Methods
The articles and journals used in this review were found
on PubMed, Ebsco, and Google Scholar. These articles
were carefully reviewed in order to determine their relevance to the thesis.
Discussion
Immunological Theory of Cancer
This theory has been associated with three general steps
the body constantly goes through: elimination, equilibrium
and escape. The elimination step consists of the immune
system surveying for all cancerous cells and destroying
them. However, there are times when tumorous cells remain undetected while remaining dormant. This period is
defined as equilibrium because there are cancerous cells
in the body, but they are not doing any harm. The final
step is escape in which the tumor gains dominance over
the immune system and starts spreading (Lopez, et al.,
2016). This implies that the immune system’s activity and
5
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ability to detect cancerous cells is important before the
cancer gets out of hand.
To try to determine how immune activity affects cancer,
residents of Japan, mostly above 40, were given a questionnaire that covered 90 lifestyle factors. People who
participated in the study gave a peripheral blood sample after fasting for over 12 hours. A follow-up was performed 11 years later where cancer incidence and death
totals were gathered. Based on the questionnaire, each
patient was assessed for cancer risk at one of three levels,
low, medium, or high. Of the 8552 individuals who took
the survey, 211 of the 3625 whose blood was sampled
were identified as cancer cases. A number of the cases
had to be excluded based on age, blood samples being
inaccessible, etc.The total number of cases remaining was
154, 92 men and 62 women. Accounting for age, it was
found that patients with lower cytotoxicity activity, were
at a significantly higher risk for developing cancer when
compared to those with medium or high activity (Imai,
et al., 2000). This study points to the fact that cytotoxic
activity can help a person fight cancer, further illustrating
that the immune system plays a role in cancer treatment.
A specific type of immunotherapy is currently being
developed in which some of the patient’s T-cells are
extracted and modified to become chimeric antigen receptor t-Cells (CAR-T cells). These T-cells are then given
artificial receptors that are from monoclonal antibodies
which allow the CAR-T cell to bind to the cancer cells.
The patient is then treated with chemotherapy to eliminate any immunosuppressant activity in the body. The
CAR-T cells are then injected and are free to attack the
cancer cells. This treatment sounds perfect but there are
some complications that arise. Cytokine release syndrome (CRS) is a life-threatening complication in which
the immune system goes into a state of being overly active and releases an excessive number of cytokines which
results in organ toxicity. CRS is manageable but one has
to be conscious of it when treating a patient with CAR-T.
Another complication that can arise is CAR-T cell related
encephalopathy syndrome. This syndrome can result in
some patients feeling slightly disoriented while others can
have seizures (Graham, et al., 2018). This methodology of
cancer treatment is new but is showing great promise. It
shows that the immune system, under careful monitoring,
can be harnessed to fight cancers.
A person’s immune system doesn’t allow cancer cells
to grow because the natural killer cells, or NK cells detect the cancers and kill them. These cells can identify a
cancerous cell because they identify which cells are “not
self” cells by searching for specific receptors that only
one’s own cells have. Therefore, they find the cancer cell
6

and kill it before it starts growing. Although some cancer
cells go undetected, there are researchers who believe
that the NK cells can be used to kill an active cancer.
A new treatment is being studied in which NK cells are
being combined with the concept of CAR-T cells creating CAR-NK cells. These cells have several advantages
over CAR-T cells. Firstly, because NK cells have natural
receptors for tumors, they have an easier time identifying cancer cells even if the CAR portion of the cell is
downregulated by the cancer. Secondly, CAR-NK cells do
not undergo clonal expansion or immune rejection thus
eliminating the issue of cytokine release syndrome that
is present with CAR-T cells. Lastly, HLA matching is not
necessary for CAR-NK cells, which means the graph-versus-host disease is not an issue when it comes to CARNK cell treatment. Currently there is not enough clinical
data to fully implement the treatment, however, there are
studies being performed to help investigate new treatment options. For example, CAR-NK cells are being researched to help determine their ability to fight hematological and solid tumors, including glioblastoma, prostate
cancer, and ovarian cancer (Hu, et al., 2019). While this
treatment is in very early stages it has had great results
thus far. If this treatment can prove to be effective it can
have massive implications in the successful treatment of
cancers because there are few side-effects.
Dendritic cells are another one of the immune cells
being used to fight cancer. Dendritic cells function as an
antigen presenting cell meaning, when it recognizes an
antigen it alerts the body to produce antibodies. There
are vaccines that have been proven to work that are prepared by removing a patient’s dendritic cells and “teaching” them to recognize cancer cells, then reinjecting them
into the patient. Once these dendritic cells are in the
bloodstream, they can identify the cancer cells and initiate
a T-Cell response to them. However, there were several
issues when the dendritic cells were taken from ex vivo
and put inside patients. Firstly, some patients experienced
a T-cell response from the injection, but it did not result
in significant improvement. This alteration in functionality could be a result of the cells being transferred from
an in vivo environment to an ex vivo environment, then
returned to in vivo. Another issue with the vaccine is
that the process is very time-consuming and expensive.
Lastly, the dendritic cell vaccine is reliant on the patient’s
immune system and its function. Because of this, in vivo
preparation of the dendritic cell is still being perfected
(Le Gall, et al., 2018).This technique can be very helpful to
cancer patients as often the cancer proliferates because
the immune system fails to recognize the cancer cells.
With this treatment the incidents of cancer cells going
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undetected can be virtually eliminated resulting in the
body halting the cancer cells growth.
Another form of immunotherapy using dendritic cells
is called dendritic-cell cytokine induced killer cells (DCCIK). In the study, there were several criteria that had to
be met when determining who was an appropriate candidate. The first requirement was that the patients had to
have advanced cancer (stages 3-5). Secondly, prior to this
study, patients had to have received first-line treatment,
including surgery, adjuvant chemotherapy and/or radiotherapy. The study examined a total of 142 patients with
histologically confirmed colorectal carcinoma, 71 were
treated with DC-CIK and 71 were not. Patients were examined at three separate times, after 1, 3 and 5 years.The
retrospective study found that patients who were treated
with DC-CIK had 1,3 and 5-year prolonged progression
free survival and overall survival versus those who were
not treated. Minor side-effects were experienced by the
patients treated with DC-CIK such as mild fever, chills,
fatigue, while three also developed a headache and one
developed chest tightness and hypotension. While these
symptoms cannot be ignored, in the grand scheme of cancer treatment these side-effects are very mild. This study
shows the effectiveness of DC-CIK and its ability to combat colorectal cancer in patients who were treated with
first-line treatments (Xie, et al., 2017). While this study
has its limitations because it required first line treatment
such as surgery, it does provide a powerful tool for patients who have already gone through or may require first
line treatments.
The examples listed above all seem to point to the accuracy of the immunological theory of cancer. Perhaps the
most indicative proof that cancer prevention is a function
of the immune system is from a study performed several
years ago which analyzed 12 patients with glioblastoma
who received regular course of immunotherapy (a dendritic cell vaccine). However, a few patients were also
given a tetanus vaccine. The patients who were given the
immunotherapy and the tetanus vaccine lived between
four to eight years after their treatment.The patients who
received the immunotherapy with another placebo drug
lived only 11 months following their treatment (Mitchell,
et al., 2015).The reason the tetanus shot impacts the cancer defense is because once given, the body begins to
create t-cells as a typical reaction to a vaccine. Due to this
additional t-cell production the body was more prepared
to fight the cancer as well (Haelle, 2015).While this study
was performed on a small sample size the results point to
the same conclusion as the previous studies; it illustrates
the role the immune system plays when fighting cancer.
These are just some of the treatments in development,

all working under the assumption of the immunological
theory of cancer being correct. As it stands, the treatments appear promising and with further research they
can hopefully be perfected and cancer patients can be
cured with minimal side effects. All the studies cited point
to the immunological theory of cancer as a very real and
likely explanation for cancer development.
Somatic Mutation Theory of Cancer
The somatic mutation theory analyzes the development
of cancer by looking at genetic factors. The specific genetic variances in squamous cell carcinoma (SCC), adenocarcinoma (AC), and adenosquamous carcinoma (ASC), 3
types of cervical cancers, were analyzed. Three hundred
and one patients with SCC, AC, or ASC who were all
treated with radical hysterectomy with lymphadenectomy as their primary treatment were analyzed. All follow-up data was obtained 5 years after primary treatment. One hundred and sixty-six (55%) of the patients
had SCC, fifty-five (18%) had AC and eighty (27%) had
ASC. In 103 of the tumors there were 123 somatic mutations detected as roughly 4% of the tumors had multiple
mutations.The specific mutations were identified for each
cancer. The PIK3CA was most common in SCC and ASC
while KRAS was most common in AC. However, in each
type of cervical cancer there was not only one mutation
rather there were several mutations found across multiple genes such as, PTEN, PPP2R1A, CTNNB1, CDKN2A,
FBXW7, FGFR3, NRAS, and HRAS. The KRAS mutation
is not exclusive to cervical cancers as it has also been
linked to colorectal, lung and pancreatic cancers. KRAS
and PIK3CA mutations were both not associated with
survival; however a clear trend of lower survival rate was
in patients carrying a PIK3CA mutation (Spaans, et al.,
2015). This study points to a connection between specific
cancers and mutations that result in them. If an unknown
cancer’s genetic sequence could be inspected it could give
a clinician a clear idea of what cancer he/she is dealing
with and how to properly treat that patient.
Cervical cancers are not the only cancers to have a
gene associated with them as prostate cancers were also
found to have specific genes connected to them. These
genes were identified by looking at a prostate specific
antigen (PSA) a protease produced in the prostate, as
well as prostatic acid phosphatase (PAP). By looking at
these two markers the researchers used the technique of
guilt-by-association which works based on combinatoric
measure of association. Forty-thousand different genes
were analyzed, and each gene was determined to be
present in prostate cancers if the cDNA corresponding
to that gene is detected in the library. Upon analysis of all
7
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40,000 genes most of them were determined to not be
related to prostate cancer. However, eight of the genes
were identified as being associated with it (Walker, et al.,
1999). The extent of their association is difficult to prove
because correlation is more provable than causality, but
the association is significant none the less.
Certain genes have been identified as being related to
breast cancer that is metastatic to bone. One hundred
and seven breast cancer patients who had developed
metastasis had their negative-lymph nodes biopsied.
Sixty-nine of the relapses were categorized as bone
while 38 were labeled as not bone. Upon analysis, 69 significantly unique gene sets were discovered across bone
and non-bone samples. The five most common genes in
bone cancer were TFF1, TFF3, AGR2, NAT1, and CRIP1.
TFF1 was studied in 122 independent breast tumors in
node-negative patients which indicates it is the most
prevalent mutation. The researches then attempted to
predict a correlation between a cancer’s gene sets and
that cancer spreading to the bone. The samples were divided into a test set and a training set. Five hundred and
eighty-eight genes were selected and subjected to PAM
analysis. A 31-gene predictor was selected after 10-fold
cross validation that could identify relapse to the bone
at 100% sensitivity and 50% specificity. The predictor
showed 79.3% positive predictive value and TIFF1 was
present in the gene list. Two random gene sets of 50
and 100 genes were analyzed to test the validity of this
method. Twenty-nine of the 50 random genes showed
100% sensitivity and of these 29, the average specificity
is 13.2% which indicates that the 50% specificity found
by the earlier gene list is significantly higher than a random gene set. Based on SAM sets the researchers determined that the most common genes associated with
the cancer metastases were TFF1 and TFF3. TFF3 was
also found as overexpressed in some metastatic prostate cancers, while TFF1 was found to induce cellular
invasion of kidney and colon cancer (Smid, et al., 2006).
This further proves that there is a strong tie between
cancer and genetics.
In high-grade serous ovarian cancers, triple-negative breast cancers, esophageal cancers, small-cell lung
cancers, and squamous cell lung cancers, the p53 gene
is mutated in at least 80% of patients’ tissue samples
(Duffy, et al., 2017). P53 has two major functions in the
cell cycle thereby linking it to cancer. P53 serves as a
cell cycle regulator, so if the cell no longer needs to go
through the cell cycle p53 will stop the cycle. Another
function is that a normal p53 protein stops a cell that
has already grown too much and is technically cancerous by initiating apoptosis for that cell (Zilfou & Lowe,
8

2009). When p53 is mutated the cells experience uncontrolled growth either because its cell cycle is not
arrested or because a cell that is already out of control
is not sent to apoptosis.
Because of the prevalence of mutant p53 in cancer
patient’s researchers have looked into a way to stabilize
these mutant forms of p53. They analyzed mice whose
p53 proteins were removed by one of several methods.
One method was that the mice were injected with an
anti-p53 antibody in which the p53 proteins in the mice
underwent ubiquitination. Another method was by using
an adenovirus, either Ad/GFP (green fluorescent protein) or Ad/His. They found that when these mice were
exposed to a drug called CP-31398, not only was the
DNA binding activity of mutant p53 restored thus allowing cell cycle arrest and induction of apoptosis, but it
can also increase the steady-state levels of wild type p53
(Takimoto, et al., 2002). Another study showed that CP31398 also inhibited the ubiquitination of p53 proteins.
A non-small-cell lung carcinoma cell, H460, was exposed
to CP-31398 for an hour, it was then exposed to ALLN,
a proteasome inhibitor, for four hours. Another group
of cells was exposed to ALLN alone and both were
analyzed. The results showed that the cells that had
just been exposed to ALLN showed a typical pattern
of ubiquitinated p53 ladders. However, the cells treated
with a mixture of CP-31398 and ALLN or just CP-31398
alone showed no ubiquitinated p53 ladders (Wang, et al.,
2003).These two applications of CP-31398 demonstrate
how useful it can be in preventing cancer because of the
prevalence of p53 mutations in cancer patients.
Another protein that has been a target for treatment
is p21, a cell cycle inhibitor, cell proliferation effector,
and apoptosis regulator. As with p53, many cancer
patients have been shown to have their p21 proteins
mutated. Gene editing techniques such as CRISPR,
TALEN’s, ZFN’s and rAAV have all been used to change
p21 expression and have been shown to suppress tumorigenesis phenotypes and reduce drug resistance.
Several chemical treatments target p21 as well. Histone
deacetylase inhibitors help increase the expression of
p21. Trichostatin A, PAC-320, and HDAC inhibitor combined with bortezomib or doxorubicin, have shown to
enhance p21 expression in pancreatic cancer, prostate
cancer and ovarian cancer respectively (Shamloo &
Usluer, 2019). All these treatments targeting p21 can
have massive ramifications because of p21’s effect on
cell cycle arrest.
Specific genetic mutations are directly linked to specific cancers which seemingly indicates that certain
genetic mutations are linked to specific cancers, thus

Which Hypothesis Best Explains the Development of Cancer?

legitimizing the claim that cancers have genetic components to them.
Stem Cell Theory of Cancer
This theory assumes that cancer is a result of a stem cell
that is unregulated and grows uncontrollably. Because of
several unique characteristics of prostate cancer such as
histological heterogeneity, metastatic growth, drug resistance, and distant relapse after effective primary treatment, the stem cell theory was proposed as a possible
explanation for prostate cancer. It was tested by searching for stem cell markers in the cancerous tissue. While
there is not one marker specific for prostate cancer stem
cells, there are a few methods used to help identify the
stem cells such as: β1 integrins, CD133, CD44, stem cell
antigen 1 and the ABCG2-associated drug-resistance
proteins. β1 is a marker for “stemness” because it is essential for sustaining a functional stem cell population and
establishing asymmetric division. β1 is also important to
stem cell maintenance. CD133 is a marker because it is
generally found in progenitor stem cells, linking it to a
stem cell. CD133+ prostate cells use their stem cell like
features developing prostatic-like acini in immunocompromised male mice. CD44 is a cell surface protein involved in cell-to-cell interaction, migration and adhesion.
Stem cell antigen 1 is expressed in the tissue of several
stem and progenitor stem cells including, cardiac mammary, hematopoietic, testicular, integumentary and muscular. These markers have been found in prostate cancers
thus giving credence to this theory (Tu & Lin, 2012). It was
also found that cancers that had CD44 were much more
tumorigenic and metastatic than cancers without CD44.
This further proves that these markers have relevance
when it comes to identifying cancers (Patrawala, et al.,
2007). These two studies indicate these classic stem cell
markers are present in cancers and furthermore they
enhance the growth and metastasis of the cancer when
they’re present.
Breast cancer was also examined for these markers.
The researchers analyzed surgically removed breast cancer tissue in 47 cases of only invasive duct carcinoma
(IDC), 135 cases of IDC with ductal carcinoma in situ
(DCIS), 35 cases of DCIS with microinvasion, 58 cases
of pure DCIS and 73 cases of IDCs with adjacent DCIS.
Four major subtypes of breast cancer were looked for in
this analysis: luminal A, luminal B, HER2+, and basal-like.
Each subtype was defined based on certain characters,
luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/
or PR+, HER2+), HER2+ (ER−, PR−, HER2+), basal-like
(ER−, PR−, HER2−, basal cytokeratin+, and EGFR+/−).
CD44+/CD24− and CD44−/CD24+ cells were found by

way of double immunohistochemistry. It was found that
luminal A tumors were least common in DCIS with microinvasion, luminal B tumors were least common in IDC
alone, and basal-like tumors were least common in pure
DCIS groups. CD44, CD24 and ALDH-1 markers were
analyzed in normal breast tissue they were then compared to cancerous breast tissue. In normal breast tissue
CD44 was localized to the basal, myoepithelial, and a subset of luminal epithelial cells. CD24 was found on the
apical membranes of luminal cells while ALDH1 was heterogeneously expressed in luminal and basal cells. CD44
was expressed in 57% of IDC only samples, 59% IDCs
with DCIS samples, 62% of DCIS with microinvasion samples, and 85% of DCIS samples. CD24 was not nearly as
prevalent as it was present in 24% IDC only tumors, 38%
of IDC with DCIS tumors, 59% of DCIS with microinvasion tumors and 62% of DICS tumors. While ALDH1
was not commonlyf ound in any of the four subtypes, it
was far more common in IDC alone and IDC with DCIS
than the other two subtypes of DCIS with microinvasion
and DCIS alone, 9%, 6%, 3%, 3%, respectively (Park, et al.,
2010). These figures point to the fact that there is an association between stem cell markers and breast cancer,
further legitimizing the stem cell cancer theory.
Head and neck squamous cell carcinoma (HNSCC)
such as cancers of the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, salivary glands, or head and
neck lymph nodes were studied to aid in further proving
stem cell theory. Multi-modality therapy including surgery,
has been emphasized as the method of treatment, yet
the five-year survival rate for HNSCC is 0-40%, with no
significant improvements in the past 30 years. A study
was done using tissue specimens of cervical lymph nodes,
primary tumors, and normal mucosa of patients undergoing surgical treatment of squamous cell carcinomas of
multiple sites in the upper aerodigestive tract. A total of
82 primary tumors and 24 metastatic lymph nodes from
82 patients were analyzed. Several variants of CD44 were
tested for: CD44s, CD44 v3, CD44 v6, and CD44 v10. It
was found that a majority of the cells from both the primary tumors and lymph nodes presented strong expression
of all 4 variants. CD44v3, v6 and v10 had a higher proportion of being strongly expressed in lymph nodes than they
did in primary tumors. Strong expression of CD44 v3 in
primary tumors was also proven to have association with
lymph node metastasis. Strong expression of CD44 v10
in primary tumors showed association with radiation failure and with distant metastasis. The expression of CD44
v6 was significantly associated with perineural invasion.
Next, an analysis was performed with regard to disease
free survival and overall survival. Overall tumor stage was
9
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found to be correlated with shorter disease-free interval.
Non-oropharyngeal primary site, positive cervical lymph
nodes, distant metastasis, CD44 v6 and CD44 v10 expression, in primary tumors, were all significantly associated with worse disease-free survival. Prior radiation
therapy, expression of CD44s and, both the standard and
variant form of CD44, in metastatic lymph nodes, were
all not significantly associated with disease free interval
or overall survival. Expression of CD44s, v3, v6, v10 were
all associated with advanced primary tumor stage, treatment failure, reduced disease-free interval, and metastasis
(Wang, et al., 2009). These stem cell markers are all indicative of very poor prognosis in HNCSS patients.
Researchers analyzed two cell groups of one patient
who suffered from colon cancer, the primary tumor cell
(SW480) and the metastatic lymph node (SW620). These
cells were analyzed by phase contrast microscopy and
were revealed as having two separate morphologies.
SW480 was shown to have 80% of its fully adhered cells
to be irregularly shaped, while 20% were spindle-like.
SW620 displayed a more mixed morphology amongst
its cells with 53% of its adhered cells as elongated spindle-shaped and the remaining 47% were either more
rounded spindles or irregularly shaped. The two cell lines
displayed similar measures of cell growth normal to their
respective cell line’s. When measuring migratory potential, SW480 cells were found to have a significantly higher
migratory potential than SW620 cells. Several stem cell
markers were analyzed in each cell line including, CD338,
CD44, CD133, CD24 and CD49f. SW620 revealed a
50.6% proportion of CD44+/CD133+ cells and SW480
displayed 28.6%. But the proportion of CD44+/CD133cells favored SW480 over SW620 with 54.3% and 20.7%
respectively. CD44+/CD24- cells were abundant in both
cell lines with SW480 having 62.7% and SW620 having
75.3%. The presence of CD49f+/CD338- was the highest
with SW480 and SW620 expressing it at 98 and 99%.
Because of the prevalence in both groups of cell lines,
it was deemed that these stem cell markers were not
significant enough to differentiate between SW480 and
SW620 in vitro cells (Slater, et al., 2018). While utilizing
stem cells did not prove to be a method to differentiate
between colon and metastatic tumors, it does prove the
presence of these stem cell markers in cancers.
Utilizing the stem cell theory, researchers have developed a new treatment for leukemic stem cells (LSCs)
that reside mainly in the bone marrow. Chronic myeloid
leukemia (CML) and acute myeloid leukemia (AML)
were analyzed. CML is categorized as a clonal hematopoietic stem cell that is caused by a translocation of a
fusion of two parts of two separate chromosomes, ALB1
10

(chromosome 9) and BCR (chromosome 22). AML is the
most common form of adult leukemia and is categorized
by infiltration of leukemic cells into the bone marrow
and blood. The current therapies have an overall survival of roughly 40% in patients under 60 and decline by
5-15% in older patients. AML is very difficult to treat because of how drug resistant the disease is. While CML
and AML are both considered to have leukemia stem
cells, the environment of the bone marrow that contains
many growth factors only expedites the growth process.
The markers used to indicate CML LSCs are CD25 IL-1
and CD26 have been suggested as markers that are
specific to this disease as opposed to other stem cells.
CML LSCs vary from ALM LSC in that CML LSCs are
defined as CD34+/CD38- fraction whereas AML LSCs
are composed of heterogenous populations and aside
from CD34+/CD38- they also are in CD34+/CD38+ and
CD34-. The treatment method for these cancers is to
disconnect the cancer from the growth promoting bone
marrow environment thus making them more sensitive
to conventional therapy. There are several compounds
being studied as possible ways to disconnect the AML or
CML from the bone marrow such as: BL-8040, CAR-LMC,
Ruxolitinib, AMD3100, TH-302, Aflibercept, AS101, AMG
386, SRF231, TTI-621, CC90002 Hu5F9-G4, LY3039478.
These compounds all have different target cites but are
all designed to disconnect the cancer from the growth
advances provided by the bone marrow. IL-1RAP has also
been shown as a good marker to target CML LSCs in a
more selective manor because of its specific expression
in CML LSCs. Inducing apoptosis is a common approach
to AML treatment (Houshmand, et al., 2019).
Antibodies targeting IL-1RAP were thought as a possible way to treat CML LSCs without harming normal
stem cells. The antibodies mAb81.2 and mAb3F8 were
used and generated by the hybridoma technique. The cell
cultures were bone marrow and peripheral blood from
healthy volunteers and CML patients.The CML cells were
stimulated with IL-1B, IL-33, IL-36 or SCF. IL-1B and SCF
resulted in a slight expansion of CD34- CML progenitor cells. The stimulation as a result IL-1B on CD34+/
CD38- cells resulted in a 30-fold increase in cell numbers
as opposed to normal cells that responded weakly. In vivo
samples were studied to show the therapeutic effects of
IL-1RAP antibodies. Mice who expressed IL-1RAP were
treated with mAb81.2 which resulted in prolonged survival. The treatment proved to be very effective to the
point where the treatment was stopped after 45 days, yet
the mice survived an additional 12 days with 2 mice living
until day 101. Several of these mice displayed significantly
lower bone marrow leukemic cell levels compared with
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control mice. These antibodies are effective because they
block the signals of IL-1 as well as initiating effector cells
to kill tumor cells. This treatment does not affect normal
human stem cells because normal stem cells do not express IL1RAP (Agerstam, et al., 2016). This study shows
tremendous promise of utilizing the stem cell theory’s
principles as a route of treatment.
Conclusion
While there is a lot of data supporting each understanding of cancer development, there seems to be one correct
approach to cancer; it appears that the correct answer is
not one of these three theories rather a combination
of the immunological theory and the somatic mutation
theory. The immunological theory seems almost entirely
correct based on the utilization of CAR-T and CAR-NK,
DC-CIK as successful methods of treatment as well as the
case-report of a tetanus shot proving to increase cancer
prognosis. The issue with solely using the immunological
theory is that it better explains the treatment of cancer
and what should happen to prevent cancers from developing (NK cells) but it does not address why a cancer
cell forms. Rather it only states once a cancer forms the
immune system should prevent it from developing. The
somatic mutation theory explains why a cancer starts
to develop but the immunological theory explains how
to prevent it from continual growth. These theories, in
tandem, are the best explanation of cancer development.
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